Chemotherapy-induced Gonadotoxicity

Taiwanese Journal of Obstetrics and Gynecology

Volumn 49, Issue 1, 2010, Pages 1-2

  Wang, Peng Hui ^a,b   Chao, Hsiang Tai ^a,b   Chao, Kuan Chong ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GONADORELIN AGONIST;

AUTOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CRYOPRESERVATION; CYTOTOXICITY; EDITORIAL; FERTILITY; GENITAL SYSTEM DISEASE; GONADOTOXICITY; HUMAN; IRRADIATION; MALIGNANT NEOPLASTIC DISEASE; OOCYTE; OVARY FOLLICLE; OVARY FUNCTION; OVARY INSUFFICIENCY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; QUALITY OF LIFE; RISK ASSESSMENT; SELF ESTEEM; SEXUAL BEHAVIOR; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CRYOPRESERVATION; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY, FEMALE; LIBIDO; NEOPLASMS; OOCYTES; OVARIAN FAILURE, PREMATURE; RADIOTHERAPY;

EID: 77953261794     PISSN: 10284559     EISSN: 10284559     Source Type: Journal    
DOI: 10.1016/S1028-4559(10)60001-0     Document Type: Editorial

References (13)

1. Marhhom E., and Cohen I. Fertility preservation options for women with malignancies. Obstet Gynecol Surv 62 (2007) 58-72
2. Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 169 (2000) 123-131
3. Taylor E., and Gomel V. The uterus and fertility. Fertil Steril 89 (2008) 1-16
4. Cheng M.H., and Wang P.H. Uterine myoma: a condition amendable to medical therapy?. Expert Opin Emerg Drugs 13 (2008) 119-133
5. Practice Committee of American Society for Reproductive Medicine in collaboration with Society of Reproductive Surgeons. Myomas and reproductive function. Fertil Steril 90 5 Suppl (2008) S125-S130
6. Cheng M.H., Chao H.T., and Wang P.H. Medical treatment for uterine myomas. Taiwan J Obstet Gynecol 47 (2008) 18-23
7. Pan C.C., and Lee W.L. Vaginal obliteration in a woman with a history of cutaneous T-cell lymphoma: the results of combined chemotherapy-induced gonadal toxicity and lymphoma relapse. Taiwan J Obstet Gynecol 49 (2010) 69-71
8. Stroud J.S., Mutch D., Rader J., Powell M., Thaker P.H., and Grigsby P.W. Effects of cancer treatment on ovarian function. Fertil Steril 92 (2009) 417-427
9. Wang P.H., Lee W.L., Cheng M.H., Yen M.S., Chao K.C., and Chao H.T. Use of a gonadotropin-releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas. Taiwan J Obstet Gynecol 48 (2009) 133-137
10. Oktay K., and Sonmezer M. Chemotherapy and amenorrhea: risks and treatment options. Curr Opin Obstet Gynecol 20 (2008) 408-415
11. Beck-Fruchter R., Weiss A., and Shalev E. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update 14 (2008) 553-561
12. Blumenfeld Z., and von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 14 (2008) 543-552
13. Badawy A., Elnashar A., El-Ashry M., and Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91 (2009) 694-697